期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

双重打击淋巴瘤研究进展 被引量：3

Research progress of double-hit lymphoma
原文传递
导出
摘要 双重打击淋巴瘤（DHL）通常是指发生MYC基因重排,同时伴有bcl-2和（或）bcl-6基因重排的大B细胞淋巴瘤.DHL侵袭性强,常规方案治疗预后差,目前尚无标准的一线治疗方案.文章就DHL在诊断、生物学行为、预后影响因素和治疗方面的研究进展进行综述,旨在加深对DHL的理解,优化治疗策略,以期改善其预后. ＂Double-hit＂; lymphoma is usually defined to be large B-cell lymphoma with MYC gene rearrangement combined with bcl-2 and/or bcl-6 gene rearrangement.It is highly aggressive with poorer prognosis after R-CHOP treatment and so far,its optimal therapy has not been developed.This article reviewed new advances in diagnosis,biology,prognostic factors and treatment of DHL in order to deepen insights,optimize therapy and improve prognosis of DHL.
作者 李俊波 刘艳艳
机构地区 郑州大学附属肿瘤医院淋巴综合内科河南省肿瘤研究院淋巴瘤研究所
出处 《白血病．淋巴瘤》 CAS 2015年第5期314-317,共4页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金（81270570）
关键词 双重打击淋巴瘤 生物学特性 靶向治疗 Double-hit lymphoma Biology Targeted therapy
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et at. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy [ J ]. Haematologica, 2013, 98 ( 10 ) : 1554- 1562.
  • 2Barrans S, Crouch S, Smith A, et at. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab [ J ]. J Clin Oncol, 2010, 28 ( 20 ) : 3360-3365.
  • 3Foot N J, Dunn RG, Geoghegan H, et al. Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience [ J ]. J Clin Pathol, 2011, 64(9): 802-808.
  • 4Green TM, Nielsen O, De Stricker K, et at. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma [ J ]. Am J Surg Pathol, 2012, 36 ( 4 ) : 612- 619.
  • 5Horn H, Ziepert M, Becher C, et at. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma [ J ]. Blood, 2013, 121 ( 12 ) : 2253-2263.
  • 6Tzankov A, Xu-Monette ZY, Gerhard M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP [ J ]. Mod Pathol, 2014, 27 ( 7 ) : 958-971.
  • 7Green TM, Young KH, Visco C, et at. Immunohistochemical double- hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [ J ]. J Clin Oncol, 2012, 30 ( 28 ) : 3460-3467.
  • 8Hu S, Xu-Monette ZY, Tzankov A, et at. MYC / BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program [ J ]. Blood, 2013, 121 ( 20 ) : 4021-4031.
  • 9Perry AM, Crockett D, Dave B J, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases [ J ]. Br J Haematol, 2013, 162( 1 ) : 40-49.
  • 10Hummel M, Bentink S, Berger H, et at. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling [ J ]. N Eng] J Med, 2006, 354 ( 23 ) : 2419-2430.

同被引文献7

引证文献3

二级引证文献9

白血病．淋巴瘤
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部